Admission lipoprotein-associated phospholipase A2 activity is not associated with long-term clinical outcomes after ST-segment elevation myocardial infarction

Pier Woudstra; Peter Damman; Wichert J. Kuijt; Wouter J. Kikkert; Maik J. Grundeken; Peter M. van Brussel; An K. Stroobants; Jan P. van Straalen; Johan C. Fischer; Karel T. Koch; José P. S. Henriques; Jan J. Piek; Jan G. P. Tijssen; Robbert J. de Winter

doi:https://doi.org/10.1371/journal.pone.0096251

Admission lipoprotein-associated phospholipase A2 activity is not associated with long-term clinical outcomes after ST-segment elevation myocardial infarction

Pier Woudstra, Peter Damman, Wichert J. Kuijt, Wouter J. Kikkert, Maik J. Grundeken, Peter M. van Brussel, An K. Stroobants, Jan P. van Straalen, Johan C. Fischer, Karel T. Koch, José P. S. Henriques, Jan J. Piek, Jan G. P. Tijssen, Robbert J. de Winter

Research output: Contribution to journal › Article › Academic › peer-review

2 Citations (Scopus)

Abstract

Lipoprotein-associated phospholipase A2 (Lp-PLA2) activity is a biomarker predicting cardiovascular diseases in a real-world. However, the prognostic value in patients undergoing primary percutaneous coronary intervention (pPCI) for ST-segment elevation myocardial infarction (STEMI) on long-term clinical outcomes is unknown. Lp-PLA2 activity was measured in samples obtained prior to pPCI from consecutive STEMI patients in a high-volume intervention center from 2005 until 2007. Five years all-cause mortality was estimated with the Kaplan-Meier method and compared among tertiles of Lp-PLA2 activity during complete follow-up and with a landmark at 30 days. In a subpopulation clinical endpoints were assessed at three years. The prognostic value of Lp-PLA2, in addition to the Thrombolysis In Myocardial Infarction or multimarker risk score, was assessed in multivariable Cox regression. The cohort (n = 987) was divided into tertiles (low <144, intermediate 144-179, and high >179 nmol/min/mL). Among the tertiles differences in baseline characteristics associated with long-term mortality were observed. However, no significant differences in five years mortality in association with Lp-PLA2 activity levels were found; intermediate versus low Lp-PLA2 (HR 0.97; CI 95% 0.68-1.40; p = 0.88) or high versus low Lp-PLA2 (HR 0.75; CI 95% 0.51-1.11; p = 0.15). Both in a landmark analysis and after adjustments for the established risk scores and selection of cases with biomarkers obtained, non-significant differences among the tertiles were observed. In the subpopulation no significant differences in clinical endpoints were observed among the tertiles. Lp-PLA2 activity levels at admission prior to pPCI in STEMI patients are not associated with the incidence of short and/or long-term clinical endpoints. Lp-PLA2 as an independent and clinically useful biomarker in the risk stratification of STEMI patients still remains to be proven

Original language	English
Pages (from-to)	e96251
Journal	PLOS ONE
Volume	9
Issue number	5
DOIs	https://doi.org/10.1371/journal.pone.0096251
Publication status	Published - 2014

Access to Document

https://doi.org/10.1371/journal.pone.0096251

Cite this

Woudstra, P., Damman, P., Kuijt, W. J., Kikkert, W. J., Grundeken, M. J., van Brussel, P. M., Stroobants, A. K., van Straalen, J. P., Fischer, J. C., Koch, K. T., Henriques, J. P. S., Piek, J. J., Tijssen, J. G. P., & de Winter, R. J. (2014). Admission lipoprotein-associated phospholipase A2 activity is not associated with long-term clinical outcomes after ST-segment elevation myocardial infarction. PLOS ONE, 9(5), e96251. https://doi.org/10.1371/journal.pone.0096251

@article{171b1023b195470f87501d75b8a4a87e,

title = "Admission lipoprotein-associated phospholipase A2 activity is not associated with long-term clinical outcomes after ST-segment elevation myocardial infarction",

abstract = "Lipoprotein-associated phospholipase A2 (Lp-PLA2) activity is a biomarker predicting cardiovascular diseases in a real-world. However, the prognostic value in patients undergoing primary percutaneous coronary intervention (pPCI) for ST-segment elevation myocardial infarction (STEMI) on long-term clinical outcomes is unknown. Lp-PLA2 activity was measured in samples obtained prior to pPCI from consecutive STEMI patients in a high-volume intervention center from 2005 until 2007. Five years all-cause mortality was estimated with the Kaplan-Meier method and compared among tertiles of Lp-PLA2 activity during complete follow-up and with a landmark at 30 days. In a subpopulation clinical endpoints were assessed at three years. The prognostic value of Lp-PLA2, in addition to the Thrombolysis In Myocardial Infarction or multimarker risk score, was assessed in multivariable Cox regression. The cohort (n = 987) was divided into tertiles (low <144, intermediate 144-179, and high >179 nmol/min/mL). Among the tertiles differences in baseline characteristics associated with long-term mortality were observed. However, no significant differences in five years mortality in association with Lp-PLA2 activity levels were found; intermediate versus low Lp-PLA2 (HR 0.97; CI 95% 0.68-1.40; p = 0.88) or high versus low Lp-PLA2 (HR 0.75; CI 95% 0.51-1.11; p = 0.15). Both in a landmark analysis and after adjustments for the established risk scores and selection of cases with biomarkers obtained, non-significant differences among the tertiles were observed. In the subpopulation no significant differences in clinical endpoints were observed among the tertiles. Lp-PLA2 activity levels at admission prior to pPCI in STEMI patients are not associated with the incidence of short and/or long-term clinical endpoints. Lp-PLA2 as an independent and clinically useful biomarker in the risk stratification of STEMI patients still remains to be proven",

author = "Pier Woudstra and Peter Damman and Kuijt, {Wichert J.} and Kikkert, {Wouter J.} and Grundeken, {Maik J.} and {van Brussel}, {Peter M.} and Stroobants, {An K.} and {van Straalen}, {Jan P.} and Fischer, {Johan C.} and Koch, {Karel T.} and Henriques, {Jos{\'e} P. S.} and Piek, {Jan J.} and Tijssen, {Jan G. P.} and {de Winter}, {Robbert J.}",

year = "2014",

doi = "https://doi.org/10.1371/journal.pone.0096251",

language = "English",

volume = "9",

pages = "e96251",

journal = "PLOS ONE",

issn = "1932-6203",

publisher = "Public Library of Science",

number = "5",

}

Woudstra, P, Damman, P, Kuijt, WJ, Kikkert, WJ, Grundeken, MJ, van Brussel, PM, Stroobants, AK, van Straalen, JP, Fischer, JC , Koch, KT , Henriques, JPS , Piek, JJ , Tijssen, JGP & de Winter, RJ 2014, 'Admission lipoprotein-associated phospholipase A2 activity is not associated with long-term clinical outcomes after ST-segment elevation myocardial infarction', PLOS ONE, vol. 9, no. 5, pp. e96251. https://doi.org/10.1371/journal.pone.0096251

TY - JOUR

T1 - Admission lipoprotein-associated phospholipase A2 activity is not associated with long-term clinical outcomes after ST-segment elevation myocardial infarction

AU - Woudstra, Pier

AU - Damman, Peter

AU - Kuijt, Wichert J.

AU - Kikkert, Wouter J.

AU - Grundeken, Maik J.

AU - van Brussel, Peter M.

AU - Stroobants, An K.

AU - van Straalen, Jan P.

AU - Fischer, Johan C.

AU - Koch, Karel T.

AU - Henriques, José P. S.

AU - Piek, Jan J.

AU - Tijssen, Jan G. P.

AU - de Winter, Robbert J.

PY - 2014

Y1 - 2014

N2 - Lipoprotein-associated phospholipase A2 (Lp-PLA2) activity is a biomarker predicting cardiovascular diseases in a real-world. However, the prognostic value in patients undergoing primary percutaneous coronary intervention (pPCI) for ST-segment elevation myocardial infarction (STEMI) on long-term clinical outcomes is unknown. Lp-PLA2 activity was measured in samples obtained prior to pPCI from consecutive STEMI patients in a high-volume intervention center from 2005 until 2007. Five years all-cause mortality was estimated with the Kaplan-Meier method and compared among tertiles of Lp-PLA2 activity during complete follow-up and with a landmark at 30 days. In a subpopulation clinical endpoints were assessed at three years. The prognostic value of Lp-PLA2, in addition to the Thrombolysis In Myocardial Infarction or multimarker risk score, was assessed in multivariable Cox regression. The cohort (n = 987) was divided into tertiles (low <144, intermediate 144-179, and high >179 nmol/min/mL). Among the tertiles differences in baseline characteristics associated with long-term mortality were observed. However, no significant differences in five years mortality in association with Lp-PLA2 activity levels were found; intermediate versus low Lp-PLA2 (HR 0.97; CI 95% 0.68-1.40; p = 0.88) or high versus low Lp-PLA2 (HR 0.75; CI 95% 0.51-1.11; p = 0.15). Both in a landmark analysis and after adjustments for the established risk scores and selection of cases with biomarkers obtained, non-significant differences among the tertiles were observed. In the subpopulation no significant differences in clinical endpoints were observed among the tertiles. Lp-PLA2 activity levels at admission prior to pPCI in STEMI patients are not associated with the incidence of short and/or long-term clinical endpoints. Lp-PLA2 as an independent and clinically useful biomarker in the risk stratification of STEMI patients still remains to be proven

AB - Lipoprotein-associated phospholipase A2 (Lp-PLA2) activity is a biomarker predicting cardiovascular diseases in a real-world. However, the prognostic value in patients undergoing primary percutaneous coronary intervention (pPCI) for ST-segment elevation myocardial infarction (STEMI) on long-term clinical outcomes is unknown. Lp-PLA2 activity was measured in samples obtained prior to pPCI from consecutive STEMI patients in a high-volume intervention center from 2005 until 2007. Five years all-cause mortality was estimated with the Kaplan-Meier method and compared among tertiles of Lp-PLA2 activity during complete follow-up and with a landmark at 30 days. In a subpopulation clinical endpoints were assessed at three years. The prognostic value of Lp-PLA2, in addition to the Thrombolysis In Myocardial Infarction or multimarker risk score, was assessed in multivariable Cox regression. The cohort (n = 987) was divided into tertiles (low <144, intermediate 144-179, and high >179 nmol/min/mL). Among the tertiles differences in baseline characteristics associated with long-term mortality were observed. However, no significant differences in five years mortality in association with Lp-PLA2 activity levels were found; intermediate versus low Lp-PLA2 (HR 0.97; CI 95% 0.68-1.40; p = 0.88) or high versus low Lp-PLA2 (HR 0.75; CI 95% 0.51-1.11; p = 0.15). Both in a landmark analysis and after adjustments for the established risk scores and selection of cases with biomarkers obtained, non-significant differences among the tertiles were observed. In the subpopulation no significant differences in clinical endpoints were observed among the tertiles. Lp-PLA2 activity levels at admission prior to pPCI in STEMI patients are not associated with the incidence of short and/or long-term clinical endpoints. Lp-PLA2 as an independent and clinically useful biomarker in the risk stratification of STEMI patients still remains to be proven

U2 - https://doi.org/10.1371/journal.pone.0096251

DO - https://doi.org/10.1371/journal.pone.0096251

M3 - Article

C2 - 24788873

SN - 1932-6203

VL - 9

SP - e96251

JO - PLOS ONE

JF - PLOS ONE

IS - 5

ER -